Graphene Photothermal Adjuvant Therapy for Mild Corona Virus Disease 2019: A Prospective Randomized Controlled Trial
NCT ID: NCT05651815
Last Updated: 2022-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
270 participants
INTERVENTIONAL
2022-11-22
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition, treatment groups will undergo Graphene adjuvant therapy 30 minutes per day for 7 d.
Upon completion of the treatment protocol, specific study endpoints will be compared between the treatment and control groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Graphene adjuvant therapy combined with conventional therapy group (treatment group)
Graphene adjuvant therapy combined with conventional therapy group (treatment group)：Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.
Graphene spectrum light wave therapy room
Undergo 30-min of graphene adjuvant therapy every day for 7 d.
Conventional therapy group (control group)
Conventional therapy group (control group)：Patients will only receive the conventional treatment for COVID-19.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Graphene spectrum light wave therapy room
Undergo 30-min of graphene adjuvant therapy every day for 7 d.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18-60 years (inclusive).
* No later than 48 h after testing positive and the onset of clinical symptoms
* Sign informed consent form.
Exclusion Criteria
* Resting heart rate over 120 beats per minute.
* Coronary heart disease patients with acute cardiac insufficiency.
* Acute exacerbation of chronic obstructive pulmonary disease（COPD）.
* Uncontrolled hypertension \[resting systolic blood pressure(SBP) more than 180 mmHg and diastolic blood pressure(DBP) more than 90 mmHg\]; uncontrolled diabetes(Random Plasma Glucose, RPG\>16.7mmol/L, HbA1C\>7.0%)
* Patients with severe cardiovascular, hepatic, renal and hematopoietic diseases.
* Pregnant or menstruating woman.
* Known or suspected history of active tuberculosis or extrapulmonary tuberculosis, patients with brucellosis, pneumonia-related illness from other causes
* COVID-19 patients for the second or more times
* Those who cannot cooperate due to various reasons
* Body temperature: more than 38℃.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hohhot First Hospital
UNKNOWN
Southeast University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Songqiao Liu
Zhongda Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Songqiao Liu, PhD.
Role: STUDY_CHAIR
Southeast University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hohhot First Hospital
Hohhot, Inner Mongolia, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Junjing Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB2022075
Identifier Type: -
Identifier Source: org_study_id